These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Metabolism and disposition of imatinib mesylate in healthy volunteers. Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710 [TBL] [Abstract][Full Text] [Related]
8. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects. Kim KA; Park SJ; Kim C; Park JY Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561 [TBL] [Abstract][Full Text] [Related]
9. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865 [TBL] [Abstract][Full Text] [Related]
10. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers. Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615 [TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pavlovsky C; Egorin MJ; Shah DD; Beumer JH; Rogel S; Pavlovsky S Pharmacotherapy; 2009 Sep; 29(9):1152-6. PubMed ID: 19698017 [TBL] [Abstract][Full Text] [Related]
13. Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. Jung JA; Kim N; Yang JS; Kim TE; Kim JR; Song GS; Kim H; Ko JW; Huh W Drug Res (Stuttg); 2014 Dec; 64(12):651-5. PubMed ID: 24549963 [TBL] [Abstract][Full Text] [Related]
14. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Filppula AM; Tornio A; Niemi M; Neuvonen PJ; Backman JT Clin Pharmacol Ther; 2013 Sep; 94(3):383-93. PubMed ID: 23657159 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819 [TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. van Erp NP; Gelderblom H; Karlsson MO; Li J; Zhao M; Ouwerkerk J; Nortier JW; Guchelaar HJ; Baker SD; Sparreboom A Clin Cancer Res; 2007 Dec; 13(24):7394-400. PubMed ID: 18094422 [TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Ramanathan RK; Egorin MJ; Takimoto CH; Remick SC; Doroshow JH; LoRusso PA; Mulkerin DL; Grem JL; Hamilton A; Murgo AJ; Potter DM; Belani CP; Hayes MJ; Peng B; Ivy SP; J Clin Oncol; 2008 Feb; 26(4):563-9. PubMed ID: 18235115 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601 [TBL] [Abstract][Full Text] [Related]
20. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Larson RA; Druker BJ; Guilhot F; O'Brien SG; Riviere GJ; Krahnke T; Gathmann I; Wang Y; Blood; 2008 Apr; 111(8):4022-8. PubMed ID: 18256322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]